Intravenous infusions typically take 1–2 hours; patients are monitored for 2–4 hours post-procedure and may resume normal activity within 24 hours if no adverse reactions occur. Mild systemic symptoms—fatigue, low-grade fever—can appear within 48 hours. Limb-specific pain may initially intensify before improvement, a phenomenon sometimes attributed to inflammatory response. Full assessment of therapeutic benefit requires 8–12 weeks.
Two registered clinical trials are actively investigating stem cell interventions in CRPS populations. One multicentre trial examined intravenous allogeneic placental MSCs in 34 CRPS patients; preliminary results reported pain reduction (measured on 0–100 numerical rating scale) averaging 28–32 points at 12 weeks, compared to 8–12 points in sham controls. A second smaller trial of neurogenic precursor cells showed subjective functional improvement in hand dexterity tasks. Neither trial has reported long-term follow-up beyond 6 months. No major efficacy data have been published in peer-reviewed journals. Mechanistic research continues.
Am I a candidate? → · Complex Regional Pain Syndrome: full overview → · Complex Regional Pain Syndrome cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment